Eleven teenage boys with bilateral anorchia and 12 with gonadotrophin deficiency were treated by injections of testosterone ester (enanthate) at an initial dose of 100 mg every six to eight weeks, rising to 250 mg every four weeks after three to four years. In the anorchic boys average adult height was 177-1 cm, compared with a mean mid-parental height of 174-4 cm, and mean predicted adult heights of 177-0 cm (Tanner-Whitehouse method) and 178-0 cm (Bayley-Pinneau method). In the patients with gonadotrophin deficiency, mean adult height was 176-9 cm, compared with a mean mid-parental height of 176*1 cm, and mean predicted adults heights of 174-0 cm (Tanner-Whitehouse method) and 177-3 cm (Bayley-Pinneau method). We conclude that this testosterone regimen allows achievement of full growth potential in such patients.
During the last 20 years treatment with depot testosterone by intramuscular injection has become well established in the management of boys with different disorders of puberty. Initially introduced for the management of anorchia,' 2 testosterone has been widely used in the management of constitutional delay of puberty,25 and gonadotrophin deficiency either as an isolated defect or as part of a wider range of anterior pituitary failure.2 5 6 Though early reports suggested that testosterone treatment might be associated with some reduction in adult height because of rapid advancement in bone age, 7 it is now believed that treatment with low doses of testosterone has no ill effect on ultimate height. Most of the studies supporting this view, however, have been in patients receiving relatively short term courses of testosterone.
The present retrospective study on the effects of testosterone on boys with anorchia or gonadotrophin deficiency was carried out to confirm that the testosterone regimen that had been used had no significant ill effects on adult height. The study also provided an opportunity to compare two different methods of assessing bone age and predicting adult height. In the boys with gonadotrophin deficiency, mean growth velocity increased from 4-8 cm/ year to 7-1 cm/year during the first year of treatment, and then fell to 5 9 cm/year and 5 8 cm/year over the next two years, respectively. (table 3) . Mean adult height (177-1 cm) for the patients with anorchia was slightly less than mean predicted height using the Bayley-Pinneau method (178 1 cm) and almost exactly the same as the mean height obtained by the method of Tanner-Whitehouse (177-0 cm). Mean adult height in these patients was 2-6 cm above mean mid-parental height.
In the patients with gonadotrophin deficiency the mean adult height was 176-9 cm, compared with a mean mid-parental height of 176-1 cm. the mean predicted height using the Bailey and Pinneau method was 177-3 cm and using the method of Tanner-Whitehouse was 174-0 cm, 2-9 cm less than the height attained.
Discussion
Testosterone treatment is well established in the management of delayed or absent male puberty. In an early paper, Aynsley-Green et al described the beneficial effect of treatment in a group of boys with anorchia.' Since then there have been many accounts of its use in boys with constitutional delay of puberty"5 and in chronic medical disorders which are associated with delayed puberty, such as cystic fibrosis.'2 In addition, short term treatment with testosterone has been recommended for differentiating between constituional delay in puberty or gonadotrophin deficiency and growth hormone insufficiency. '3 Treatment with testosterone is also the main method of inducing secondary sexual development in boys with hypopituitarism that is caus-ing growth hormone deficiency associated with gonadotrophin deficiency. 2 Our results provide further evidence for the safety and efficacy of testosterone ester given by intramuscular injection to produce virilisation in boys with hypogonadism. The regimen that was used produced progressive development of the genitalia similar to that seen in normal male puberty, and in all cases development of the penis and scrotum was judged to be satisfactory after three to four years of treatment. The testosterone regimen does not completely mimic the normal changes of puberty, however, particularly with respect to the timing of peak height velocity. In normal puberty peak height velocity is reached about 18-24 months after the onset of puberty, at a time when testicular development is already well established. In this study, and in the study described by Aynsley-Green et al,' the most rapid growth occurred during the first year of treatment, and over the next two years growth velocity declined. These findings suggest that the initial dose of testosterone used in both studies may have been too high, and it might be more physiological to use a smaller dose of depot testosterone during the early stages of androgen replacement. Despite this difference in the timing of peak height velocity, however, the regimen described seems to be associated with realisation of full growth potential, judged from both mid-parental heights and adult height predictions based on two different methods.
In our study many of the subjects did not begin treatment until well after the normal age at which puberty begins. This was at least partly related to the late referral of some patients, particularly those with gonadotrophin deficiency who had initially been considered to have straightforward constitutional delay of puberty. We emphasise that such a delay in initiating treatment is inappropriate in most cases, and that the aim of treatment should be to try to mimic the timing of normal puberty as closely as possible, probably by using a lower starting dose of testosterone than that used in our patients.
The effect of testosterone, on body habitus and muscle mass is well known, and in our patients this was probably reflected in the increased body mass index that was seen with continued treatment. This increase in both anorchic and hypogonadotrophic patients was similar during a three year period. The initial body mass index was, however, higher in the hypogonadotrophic patients. We do not know whether this is a consistent feature of gonadotrophin deficiency or whether the finding could be related to the relatively advanced age at which some of the patients started treatment. 
